Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer’s disease (AD).
The studies were published in Alzheimer’s Research & Therapy, Journal of Alzheimer’s Disease, and Radiology. According to Nexalin, taken together, the results provide a convergent body of evidence validating the company’s differentiated, non-invasive approach to treating AD. Nexalin believes this will position it as a potential paradigm-shifting solution for patients seeking accessible, safe, and effective alternatives to drug regimens—at considerably less costs than pharmaceuticals.
In a statement, Mark White, CEO of Nexalin, commented, “The strength of these three publications lies in their convergence. Each study explores a different dimension of the disease-cognition, regional activity, and functional connectivity—and all point to the same conclusion: Nexalin’s DIFS technology has the potential to restore brain networks and improve cognitive function in AD. Collectively, they represent one of the most compelling non-invasive data sets to date in this field.”
